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Acute lung injury is a severe complication to acute pancreatitis and a significant health
problem associated with a considerable mortality. Underlying mechanisms are complex and
poorly understood, although recent insights have identified several inflammatory profiles
and cellular components involved to varying degrees during different phases of pancreatitis
exacerbation and acute lung injury. This review aims to highlight the current understanding
of the inflammatory and cellular components involved in and responsible for the associations
of acute pancreatitis and acute lung injury, with the hope of thereby providing an increased
understanding of the underlying mechanisms. In addition, novel experimental models of modu-
lating the pancreatitis-associated acute lung injury are presented, interventions that may be
of potential future clinical value.
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Acute pancreatitis (AP) is a condition with an annual inci-
dence of approximately 300 cases/million inhabitants in the
Western world. The majority of cases are classified as mild
according to the Atlanta Classification,1 while about 15%
have severe acute pancreatitis with an associated mortality
of around 10%.2
Hypovolemia (<100 mmHg) at admission is among
predictive factors affecting the course of disease, which
correlates with both morbidity and increased mortality in
patients with predicted severe acute pancreatitis. In addi-
tion, there appears to be a correlation between hypovolemia
and the magnitude of the systemic inflammatory response
syndrome (SIRS), in which e.g. increased endothelial barrier
permeability and profound release of pro-inflammatory
chemokines and cytokines may cause organ dysfunction. It
has thereby been acknowledged that early and carefully
monitored fluid resuscitation influence the course of disease,
probably by minimizing ischemia and reperfusion injury, and
the concomitant pro-inflammatory response.3e5
Acute respiratory failure comprises both acute lung injury
(ALI) and acute respiratory distress syndrome (ARDS), both
with typical radiological findings as well as physiological
changes. The arterial oxygen pressure and inspired oxygen
concentration ratio ðPaO2=FiO2Þ is utilized to distinguish
the two conditions, where ALI is defined as
ðPaO2=FiO2Þ  300 mmHg and ARDS 200 mmHg.6 Overall, ALI
and ARDS are significant health problems accounting formortality rates between 30 and 40%. Approximately 190,000
ALI cases are reported annually in the US, responsible for up
to 74,500 deaths per year. Common causes include sepsis,
pneumonia, trauma, and acute pancreatitis.7e10 In severe
acute pancreatitis, acute lung failure is the main contrib-
uting factor to early deaths, i.e. within the first week after
admission, by developing single or multiple organ dysfunc-
tion.11,12 It has also been reported that ALI is the conse-
quence of the systemic inflammatory response, which also
regulates the magnitude of the pulmonary injury,13,14
involving granulocytes, macrophages, cytokines/chemo-
kines and intracellular signaling pathways, which are all the
topics which will be highlighted in this review.
ALI and ARDS in acute pancreatitis
In patients with acute pancreatitis, up to 20% of all deaths
occur prior to admission to hospital. In these cases, acute
lung injury seems to be the predominant cause of death.15
Acute lung injury is microscopically characterized by an
initial exudative phase during day 1e3 with a diffuse
alveolar damage, type I pneumocyte necrosis, and influx of
inflammatory cells and fluid. This is followed by a prolifer-
ative phase from about days 3e7 with lung repair, type II
pneumocyte hyperplasia and fibroblast proliferation.16
Underlying pathophysiological mechanisms for ALI
includes a variety of derangements of the normal homeo-
stasis, including pulmonary endothelial and epithelial barrier
dysfunction. In addition, neutrophils, monocytes, and
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recruited at different phases by chemokines like interleukin-
8 (IL-8) and monocyte chemoattractant protein (MCP)-1,
become activated (Fig. 1). Pancreatitis-associated ALI is
further related to specific effects on pancreatic enzymes like
proteases and phospholipase A2. Increased serum concen-
trations of phospholipase A2 has been demonstrated in severe
acute pancreatitis and correlates with the extent of pulmo-
nary complications and lung injury scores.17e19
In this review we will focus on different pathophysio-
logical mechanisms and potential interventions for the
acute lung injury associated with acute pancreatitis. The
majority of the studies referred to in this review are
experimental studies in different animal models of acute
pancreatitis.Neutrophils
Induction of pancreatitis causes a prominent assembly of
neutrophils within the capillaries of the lungs with at the
time no apparent inflammatory cell infiltration noted in the
pancreas. Neutrophils are the earliest immune cells to be
recruited to the site of injury or inflammation and are
considered to play a key role in the progression of ALI and
ARDS, as activation and transmigration of neutrophils is
a hallmark event in the progression of ALI and ARDS.20e23
The neutrophil sequestration to the lungs activates
oxygen radicals, arachidonic acid metabolism as well as
production of proteolytic and chemotactic substances inFigure 1 The alveolarecapillary barrier is formed by two separ
epithelium. The early phase of acute lung injury is characterized by
complex network of cytokines and other pro-inflammatory compoun
injury. Cytokines such as TNF-a and IL-1, secreted by lung macropha
expression by structural cells in the lung microenvironment. Cytoto
by the leukocytes recruited to the lung (e.g., neutrophils and exudneutrophils, leading to pulmonary endothelial injury. In
addition, there is evidence for interactions between gran-
ulocytes, endothelium, and endothelium-derived mediator
substances, which together can amplify the lung injury.
Ultimately, lung injury appears to result from local endo-
thelial cell injury secondary to neutrophil-generated
oxygen products that may be myeloperoxidase (MPO)
dependent.24 Since neutrophils accumulate in the lungs
during ARDS and are also present in the lungs of cerulein-
induced pancreatitis in rats, it is likely that they play an
equivalent crucial role in pancreatitis-associated ALI.20
During later phases, severe alterations of endothelial
cells, including interstitial edema formation and thickening
of the alveolar gas exchange barrier, are observed. Lung
edema, endothelial and epithelial injuries are accompanied
by an influx of neutrophils into the interstitium and bron-
cheoalveolar space.
Proof for the importance of neutrophils in ALI comes both
from clinical data and animal models. In patients with ARDS
following sepsis, the percentage of BAL polymorphonuclear
leukocytes (PMN) was higher in patients who died than in
those who survived.25 Prominent leukocyte margination in
pulmonary microvessels and edematous thickening of alve-
olar septa have been reported in an experimental model of
acute hemorrhagic pancreatitis in sheep. At later time-
intervals, a marked hemorrhagic destruction of the lungs
occurred with a complete loss of the alveolar architecture.22
Furthermore, severe endothelial cell destruction and
marked pulmonary edemawas found early after induction of
hemorrhagic pancreatitis in rats.23ate barriers, the microvascular endothelium and the alveolar
the increased permeability of the alveolarecapillary barrier. A
ds initiate and amplify the inflammatory response in acute lung
ges result in a substantial amplification of cytokine/chemokine
xic products (e.g., reactive oxygen and proteases) are secreted
ate macrophages).
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antibody-depletion of peripheral neutrophils, as well as
blockage of neutrophil adherence functions using anti-CD18
antibodies, improved the survival rate and significantly
decreased histological changes.26 Administration of anti-
neutrophil serum in an experimental diet-induced pancre-
atitis model, using choline deficient ethionine, prevented
the microvascular permeability and MPO rise in the lungs.27
The same findings were observed in caerulein-induced
pancreatitis in rats.24
Intercellular adhesion molecule-1 (ICAM-1) plays an
important role in the neutrophil-mediated pro-inflammatory
response in pancreatitis and pancreatitis-associated lung
injury. In addition, ICAM-1 and neutrophil-independent
events also contribute to the development of pancreatitis
and lung injury.28,29 Heat shock protein 72 (Hsp72) is over-
expressed in bronchial epithelium, alveolar macrophages,
infiltrating neutrophils and blood vessels in acute pancrea-
titis. It has been suggested that Hsp72 induction is mediated
by neutrophil infiltration into the lungs via P-selectin.30
In conclusion, neutrophils, interacting with ICAM-1, play
an important role in regulating the severity of pancreatitis-
associated ALI.
Macrophages
Activation of different cell populations contributes to the
generation of systemic inflammatorymediators. In particular,
peritoneal macrophages, alveolar macrophages and Kupffer
cells, activated during different stages of severe acute
pancreatitis, have been implicated to contribute to disease
progression.31e34Macrophages can be activated depending on
microenvironment through different activation pathways,
resulting in marked phenotypic heterogeneity.35,36
In vitro activation ofmacrophages occurs after treatment
with supernatants from rat pancreatic acinar cell cultures
incubated with cerulein.37 Similarly, ascitic fluid from rats
with experimentally induced pancreatitis activates macro-
phages in vitro.38,39 These results indicate that mediators
released during acute pancreatitis have the capability to
activate macrophages. Activated macrophages generate
systemic cytokine and inflammatory mediators.40
Several macrophage populations get involved in
the course of the disease. Macrophages as the main
source for the production of inflammatory mediators,
amplify the immune response during acute pancreatitis
progression.
Peritoneal macrophages
Peritoneal macrophages are exposed to profound pro-
inflammatory environment of ascitic fluid secreted by the
pancreas and become activated. This activation may be of
particular importance as inflammatory mediators released
by these macrophages into the peritoneal cavity could easily
reach the circulation, thus contributing to the systemic
inflammatory response associated with acute pancreatitis.41
Release of IL-1b and TNF-a by peritoneal macrophages
during the early stages of AP induce a cascade of additional
inflammatory cytokines, activation of neutrophils, and
induction of a net pro-inflammatory response. Cytokineneutralization has no beneficial effect on the degree of
pancreatitis, however, it attenuates the systemic stress
response and is associated with a modest decrease in
mortality.42 Abnormal trypsin activation in the pancreas
stimulates production of cytokines in rat peritoneal
macrophages and injection of trypsin into the peritoneal
cavity induces lung injury.43 The contribution of peritoneal
macrophage-derived mediators to the toxicity of ascitic
fluid was demonstrated when peritoneal lavage was carried
out before the induction of pancreatitis in order to remove
peritoneal macrophages.44
Deactivation of the activated pancreatic macrophages,
as the major source of TNF-a, in the early course of AP
increases survival and decreases the severity of disease. It
has been suggested that activation of NF-kB and p38 MAPK
in monocytes/macrophages from animals with AP might
play a role in transcription and biosynthesis of TNF-a and IL-
6.45,46 Animal experiments have indicated that sterile
cytokine-depleted ascites from AP can stimulate in vitro
cytokines production from macrophages derived from the
spleen and lungs, and induce systemic cytokine production
in vivo.47
By depleting peritoneal macrophages using liposome
encapsulated dichloromethylene biphosphonate, the
inflammation was extended from the pancreas to the
peritoneal cavity and subsequently induced SIRS, lung
injury and multiple organ failure. This somewhat contra-
dictory finding could imply a possibility of therapeutic
modification of peritoneal macrophages as a new thera-
peutic approach in patients with AP.48,49Kupffer cells
Another population of macrophages involved in the patho-
genesis of acute pancreatitis is Kupffer cells. They are the
most abundant mononuclear phagocytes in the body and
a predominant source of inflammatory cytokines released
into the systemic circulation. Kupffer cells can e.g. interact
with mediators released by a damaged pancreas or present
in ascitic fluid before they become “diluted” in the
systemic circulation.50 Pancreatic blood, but not intestinal
blood, plays a key role in liver activation during experi-
mental acute pancreatitis.51 Once the inflammatory medi-
ators reach the liver, Kupffer cells become activated and
amplify their release of cytokines into the blood stream and
thus contribute to the systemic manifestation of AP. Acti-
vated Kupffer cells release e.g. immune-regulatory and
inflammatory cytokines, reactive nitrogen intermediates
(RNI), reactive oxygen intermediates (ROI), and hydrogen
peroxide, all playing significant roles in the progression of
pancreatic inflammation into a systemic process.52 TNF-
a triggers the early events in AP and as pancreatitis prog-
resses, It reaches the liver, further manifesting the disease
outcome by causing a profound cytokine release.53 The
observation that the systemic manifestation of AP is more
severe as compared to graft pancreatitis (as the mediators
released by the pancreas in graft pancreatitis are sent
directly through the iliac vein) implicates that the liver
plays an active role in the development of lung injury
secondary to AP.54 This observation has been further
Acute lung injury in acute pancreatitis 1203confirmed by preventing the passage of blood from
pancreas to the liver.40,55
In vitro analysis of Kupffer cell activity revealed that
they also become activated by pancreatic enzymes.52,56
Inhibition of Kupffer cell activity, by gadolinium chloride
administration before the induction of acute pancreatitis,
results in reduced levels of circulating cytokines and
prevents the pathological injury in the lungs, but not the
pancreatic damage.55,57e61 These results indicate that liver
involvement and activation of hepatic macrophages amplify
the inflammatory signals induced by the pancreas and
subsequent secondary systemic organ dysfunction. Inter-
estingly, the liver itself is not affected by this process and
liver damage is not evident during the early stages of
pancreatitis.58,62Alveolar macrophages
The third family of macrophages involved in the progression
of acute pancreatitis is alveolar macrophages. It has been
postulated that alveolar macrophages (AM) are involved in
the development of acute local disorders as a consequence
of extra-pulmonary stimuli like acute pancreatitis, perito-
nitis, or trauma. Alveolar macrophages have the capacity to
secrete a vast number of chemokines, cytokines, growth
factors and reactive oxygen and nitrogen species. Hence,
they possess multiple pro- and anti-inflammatory roles in
the respiratory tract. The activation of the alveolar
macrophages leads to the recruitment of leukocytes from
the circulation, including monocytes, neutrophils and T
lymphocytes.
Alveolar and interstitial macrophages play distinct roles
in the acute lung injury associated with acute pancreatitis.
Alveolar macrophages promote an early inflammatory
response, whereas interstitial macrophages appear to have
a protective role to resolve the inflammation.63 Increased
NO synthesis related to induction of iNOS in alveolar
macrophages has been suggested to contribute to the acute
lung injury secondary to pancreatitis.54,64 The use of
phospholipase A2 (PLA2) inhibitors indicate that this
enzyme could be involved in the activation of alveolar
macrophages and generation of nitric oxide.65 PLA2 has
further been shown to regulate the cytokine production by
monocytes/macrophages as well as phagocytosis and
superoxide ðO2 Þ generation by neutrophils.66
Inhibition of NF-kB activation may reverse the lung
injury in acute necrotizing pancreatitis by inhibiting the
release of inflammatory mediators by alveolar macro-
phages.61 Neutrophil recruitment to the lungs during AP is
in part mediated by chemotactic mediators (TNF-a and MIP-
2) released by activated alveolar macrophages.64 In AP,
endothelial cells, neutrophils and macrophages release
platelet activating factor (PAF), which has been implicated
as a key mediator in the progression of AP, leading to
complications and high mortality rates.Macrophages polarization
Peritoneal macrophages frequently show a classical pro-
inflammatory M1 phenotype in AP, characterized by highexpression of TNF-a, IL-1b, IL-6, iNOS, COX-2 and lack of
changes in the mannose receptor.35,67,68
A recent study indicates that peritoneal macrophages
could be reprogrammed in vitro to activated (M2) macro-
phages by the Th2 cytokines IL-4 and IL-13, thus opening
the possibility for therapeutic modulation of macrophage
activation in the treatment of AP. M2a macrophages fail to
produce NO and to present antigens to T cells.67,69,70
Increased expression of iNOS71 and TLR450 were found in
peripheral blood monocytes from patients with severe
acute pancreatitis, indicating elevated levels of activated
monocytes in the circulation.
Interventions
Initial treatment strategies have focused on the inhibition
of macrophages. Administration of the macrophage-
pacifying compound CNI-1493, prior to the induction of
severe acute pancreatitis in rats results in an increased
survival and reduced disease progression manifested by
reduced levels of circulating enzymes, cytokines, as well as
transaminases.72,73 Macrophage ablation also confers
a protective effect on disease progression in a mice model
of adenoviral-induced pancreatitis, although reduced levels
of the potentially protective cytokine IL-10 was observed.74
In additional experimental models, the use of gadolinium
chloride to inhibit Kupffer cells,40,52 liposome encapsulated
dichloromethylene-diphosphonate to inhibit peritoneal
macrophages,50 or PAF antagonists to block the activation
of alveolar macrophages,75 resulted in modulation of the
systemic inflammatory response. Unfortunately, in these
studies the macrophage inhibitors were administered
before the induction of pancreatitis and the translation of
these findings into clinical practice is thereby difficult.
Moreover, the extensive time required for efficient
macrophage ablation or inhibition of their activity consti-
tutes a limiting factor to experimental studies. Conse-
quently, other approaches have been evaluated based on
the ability of macrophages to modify their phenotype. An
interesting approach is to polarize macrophages ex vivo
toward M2 cells and subsequently transfer these cells into
animals with acute pancreatitis.76 This approach results in
a reduction of histological score and in levels of circulating
amylase. However, the long time required to obtain polar-
ized macrophages remain and may limit its approach as
a therapeutical strategy.
Together, these studies reveal that the development of
lung injury is accompanied by dramatic changes in macro-
phages. The above referred studies demonstrate a role for
macrophages in determining the severity of the acute lung
injury, opening a novel area of investigation to identify new
therapies in the treatment of patients with acute lung
injury.
Mast cells
Mast cells are regarded as potentially important in the
initiation and/or amplification of an acute inflammatory
response.77 Activated mast cells induced by pancreatitis
appear to play a critical role in the initiation of
pancreatitis-associated lung injury. This further involves
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extra-pancreatic organs/tissues, particularly in the lungs
and colon.78 In a rat model of intraductal administration of
sodium taurodeoxycholate, the permeability of the endo-
thelial barrier significantly increased 6 h after induction of
pancreatitis. However, administration of the mast cell
stabilizer cromolyn prevented against pancreatitis-induced
endothelial barrier compromise in the lungs and systemic
histamine levels. In addition, it prevented against
a decrease in circulating PECAM-1 positive neutrophils and
monocytes/macrophages. The number of ICAM-1 and
PECAM-1 positive pulmonary neutrophils and monocytes/
macrophages decreased 6 h after induction of pancreatitis.
This indicates that mast cells may play a critical role in the
activation of leukocytes during the initiation of
pancreatitis-associated lung injury by altering adhesion
molecule expression.79 Pancreatic mast cells play an
important role in triggering the local and systemic inflam-
matory response during the early stages of acute pancrea-
titis. In contrast, pulmonary mast cells are not directly
involved in the inflammatory response related to pancre-
atic damage.80
Cytokines and chemokines
In the pathogenesis of respiratory complications following
AP, cytokines and chemokines, in particular IL-1b, IL-6, IL-
8, IL-18 and TNF-a, play major roles.81
TNF-a and IL-1b
Intravenous administration of pancreatic ascites to healthy
rats increased the leukocyte number in BAL and induced
lung injury,82 while in IL-1b/TNF-a receptor double
knockout mice, sterile, cytokine-free ascitic fluid,
collected from rats with pancreatitis, failed to induce lung
injury as observed in wild-type animals.83 Mice lacking IL-1b
converting enzyme (ICE/caspases 1) have impaired IL-1b
secretion and do not develop acute pancreatitis and
concomitant lung injury.84 ICE, i.e. caspase-1, belongs to
the caspase family of cysteine proteases which proteolyti-
cally cleaves IL-1b and IL-18 precursors into their active
forms. Caspase-1 inhibition has been effective in the
treatment of ALI in experimental SAP.85 Similarly, inhibition
of IL-1b with an IL-1 receptor antagonist, or genetic dele-
tion of IL-1b reduces the severity of experimental
pancreatitis.47,86,87
P38 MAP kinase-mediated TNF-a and nitric oxide induc-
tion play a central role in the development of SAP associ-
ated pulmonary dysfunction, and p38 MAPK inhibition
reduces the severity of lung injury.88 Down-regulation of
TNF receptor associated factor 6 (TRAF6) has been associ-
ated with increased inflammatory severity in both pancreas
and lungs, suggesting that TRAF6 is involved in the anti-
inflammatory process during AP.89
CINC/IL-8
Blockade of cytokine-induced neutrophil chemoattractant
CINC (analogous to IL-8 in humans) in a cerulein induced
acute pancreatitis model had little effect on the pancreaticdamage, while having protective effects in the lungs when
administered either prophylactically or therapeutically.90
Similarly, reduced CINC production by bronchoalveolar
macrophages after administration of the novel carbox-
amide derivative IS-741, effectively prevented
pancreatitis-associated lung injury following septic
challenge.91e93
CCR1
Activation of the chemoattractant chemokine receptor-1
(CCR1) on either peritoneal or pulmonary macrophages
leads to an autocrine process where increased levels of
TNF-a further drive induction of both a and b chemokines,
resulting in recruitment of inflammatory cells to the
pancreas and lungs. Deletion of CCR1, the receptor for MIP-
1a (CCL3) and RANTES (CCL5), had no effect on cerulein-
induced pancreatitis, while protecting from subsequent
lung injury. This was suggested to relate to decreased levels
of TNF-a, indicating an important role of CCR1 in the
extension of pancreatic injury to a systemic response.93
However, in the same model, inhibition of CXCL2 (MIP-2)
partially protected against both pancreatic and lung
injury.94
MIF, IL-18 and IL-10
Macrophage migration inhibitory factor (MIF), a pro-
inflammatory cytokine released by macrophages and
lymphocytes, is emerging as an important factor in the
pathogenesis of AP. Pre-treatment with anti-MIF antibodies
improved the survival of rats with AP.95
The ratio between pro- and anti-inflammatory mediators
can be of importance in predicting the severity of pancre-
atitis and pancreatitis-associated lung injury. The pro-
inflammatory cytokine IL-18 has been suggested to be
used as a clinical marker in screening tests. AP patients
with IL-18 levels exceeding 650 pg/ml are likely to develop
pulmonary dysfunction.96 In contrast, the anti-
inflammatory cytokine IL-10 counteracts the release of
pro-inflammatory cytokines from macrophages. The lung
injury following diet-induced pancreatitis was more
pronounced in IL-10 knockout mice than in wild-type mice,
whereas the severity of pancreatitis was similar in both
groups.97Substance P
The neuropeptide substance P is a pro-inflammatory
mediator involved in pancreatitis. The biological proper-
ties of substance P are mainly (but not exclusively) medi-
ated via the neurokinin 1 receptor (NK-1R). During acute
inflammation substance P induces chemokine release from
macrophages infiltrating local and distant damaged tissues.
It induces selective chemokine production in murine
RAW264.7 macrophage cells, as well as in primary macro-
phages.98 Mice lacking NK-1R are protected against
cerulein-induced pancreatitis and associated lung
injury.99e101 Similar findings have been observed in mice
treated with the specific NK-1R antagonist, CP-96345.
Acute lung injury in acute pancreatitis 1205Pulmonary microvascular permeability was also reduced as
a result of CP-96345 treatment.102
Deletion of the substance P gene precursor
preprotachykinin-A (PPT-A) has a protective effect against
acute pancreatitis-associated lung injury, with a partial
protection against local pancreatic damage.103 Associations
between substance P and the pro-inflammatory gaso-
transmitter hydrogen sulphide (H2S) have been demon-
strated in pulmonary inflammation and in acute
pancreatitis.104 Prophylactic or therapeutic administration
of DL-propargylglycine (PAG), an irreversible inhibitor of the
H2S synthesizing enzyme CSE, significantly reduced H2S and
substance P levels in plasma, pancreas and lungs in a cer-
ulein-induced acute pancreatitis model. In addition, PPT-
A and NK-1R mRNA expression were reduced in both
pancreas and lungs. These results suggest that the pro-
inflammatory effects of H2S in acute pancreatitis may be
mediated via the substance P/NK-1R pathway.105
Ghrelin, an anti-catabolic hormone, can significantly
down-regulate pulmonary substance P expression and
attenuate the severity of acute lung injury induced by
AP.106Platelet activating factor
Platelet-activating factor (PAF) is a pro-inflammatory
phospholipid that promotes recruitment and activation of
inflammatory cells, and is further involved in bronchocon-
striction and in altering microvascular permeability. During
pancreatitis, the levels of PAF in the pancreas increases
with disease progression and has been implicated to play
a role in the systemic involvement and associated lung
injury.107e109 Administration of the PAF degrading enzyme,
PAF acetylhydrolase, after initiation of pancreatic injury,
prevents the development of pancreatitis-associated lung
injury.109
Several PAF antagonists have been evaluated in experi-
mental models and clinical trials for the treatment of acute
pancreatitis and prevention of organ failure.75,108,110,111
PAF antagonist (TCV-309) attenuated hyperactivity of
bronchoalveolar macrophages and pancreatitis-associated
lung injury in an experimental acute pancreatitis model.
The preventive effects were associated with reduced levels
of CINC in the circulation as well as its local expression in
the lungs.112 Another PAF antagonist, BN 52021, signifi-
cantly prevented hyperamylasemia due to experimental
pancreatitis, reduced necrotic and inflammatory changes in
the pancreas and improved survival rate.113 The systemic
inflammatory response in a murine model of mild acute
pancreatitis was reduced after treatment with the PAF
antagonist lexipafant.114 Lexipafant is one of the few
interventions which has led to clinical trials. Lexipafant
treatment significantly reduced serum IL-8 and IL-6 levels,
but had no effect on serum C-reactive protein in a double-
blind, placebo-controlled study (n Z 83).115 However, in
a larger randomized, double-blind, placebo controlled,
multicenter trial (n Z 290), lexipafant had no preventive
effects on organ failure in acute pancreatitis, suggesting
that PAF antagonism alone is not sufficient to improve the
systemic inflammatory response syndrome SIRS in severe
acute pancreatitis.116Matrix metalloproteinases
Pancreatitis results in increased local and distant matrix
metalloproteinase (MMP) activity that has been suggested
to contribute to the systemic complications and pulmonary
injury. Treatment with the MMP inhibitor Batimistat (BB-94)
reduced neutrophil transmigration and alveolar-capillary
leakage in pancreatitis-associated lung injury. In addition,
the MMP inhibitor reduced the pancreatic and lung injury
and improved survival following experimental acute
pancreatitis. Further evaluation showed that MMP-9 was
highly expressed in the lungs and in neutrophil superna-
tants, suggesting an important role of neutrophil-derived
MMP-9 in the pathogenesis of pancreatitis-associated lung
injury.117,118 Specific inhibition of MMP-9 activity with
doxycycline has demonstrated similar effects.119
Poly (ADP-ribose) polymerase-1
Poly (ADP-ribose) polymerase-1 (PARP-1) is a nuclear DNA-
binding protein involved in apoptosis, cell necrosis and
organ failure in various inflammatory conditions. Genetic
deletion or pharmacological inhibition of PARP-1 attenuates
the severity of acute pancreatitis and pancreatitis-
associated lung injury. This effect may be due to preven-
tion of pancreatic cell necrosis mediated by reactive
oxygen species (ROS) released via the neutrophil enzyme
NADPH oxidase.120,121
NF-kB
NF-kB is a central transcription factor that controls the
expression of multiple inflammatory genes, such as TNF-a,
IL-6, IL-8 and inducible nitric oxide synthase (iNOS). Over-
expression of these factors can cause damage to pancreatic
and extra-pancreatic tissues in AP. A correlation between
NF-kB activation, serum amylase, reactive oxygen species
(ROS) levels and pancreatic and pulmonary tissue damage
has been implicated in the pathogenesis of AP. Inhibition of
NF-kB activation using PDTC (pyrrolidine dithiocarbamate),
prevented pancreatic damage and reactive oxygen species
(ROS) production in rat AP. PDTC treatment further reduced
the expression of iNOS mRNA and effectively improved the
severity of lung injury.122,123 Sphingosine-1-phosphate
(S1P), a biological active lipid, reduces the NF-kB activa-
tion of alveolar macrophages, which leads to prevention of
pancreatitis-associated lung injury.124
Pancreatitis-associated proteins
Pancreatitis-associated proteins (PAPs) belong to the
regenerating (Reg) secretory protein family, which is
strongly induced during acute pancreatitis. PAP has been
proposed as a potential marker for disease identification
and classification of severity of ongoing acute pancreatitis
in rats.125 Although originally identified during AP, PAPs
have been reported in e.g. Crohn’s disease, inflammatory
bowel disease, liver injury, neuronal, ovarian, and cardiac
tissue damage.126,127 Recent investigations suggest that
PAP2 is a potential mediator of early inflammation in AP,
1206 H. Akbarshahi et al.acting specifically by orchestrating the macrophage
inflammatory response through putative a PAP2 receptor. It
has also been suggested that PAP proteins mediate the
systemic inflammation response of pancreatitis.128
Further experimental interventions
Several studies have evaluated the beneficial effects of the
somatostatin analog octreotide and the flavone and anti-
inflammatory agent baicalein in experimental severe acute
pancreatitis rat models. These studies suggest that both
octreotide and baicalein effectively decrease SAP compli-
cations, protect against multiple organ injury and improve
the survival rate in SAP. The protective effects were
further accompanied with reduced serum levels of TNF-
a.129e131
Erythropoietin (EPO) administration prevented the
changes of ALI following acute necrotizing pancreatitis in
rats and decreased the levels of pro-inflammatory cyto-
kines and oxidative stress markers. EPO further inhibited
neutrophil accumulation, maintained microvascular endo-
thelial cell integrity and reduced oxidative stress-
associated lipid peroxidation.132
Pentoxifylline, a nonspecific phosphodiesterase inhib-
itor, was recently shown to have an immune modulating
role including attenuation of pro-inflammatory neutrophil
functions. Pentoxifylline significantly attenuated histolog-
ical evidence of pulmonary injury, pulmonary neutrophil
activity, and pro-inflammatory signaling in bile-induced
AP.133
Several other interventions such as rosiglitazone,
emodin, edaravone, lidocaine, propentofylline, losartan,
resveratrol and exogenous leptin have shown protective
effects on the acute lung injury due to acute
pancreatitis.134e141
Clinical studies
Several prospective randomized clinical trials have tar-
geted pancreatic injury to treat acute pancreatitis.
Protease inhibitors, such as aprotinin and gabexate mesy-
late, have not shown benefit in patients with severe acute
pancreatitis.142e144 Controlled clinical trials have failed to
demonstrate the therapeutic efficacy of antioxidants.145
Platelet-activating factor receptor antagonist, lexipafant,
reduced the severity score for all organ dysfunction in
patients with severe acute pancreatitis. However, another
study reported no efficacy of lexipafant.116 The only
treatment that improved acute pancreatitis-associated
lung injury was thoracic duct drainage, but this treatment
has not been tested in a large clinical trial.146
Conclusion
Mechanisms involved in acute lung injury (ALI) associated
with severe acute pancreatitis are complex and probably
not significantly different from the ALI caused by other
underlying disorders. We still lack effective treatment
directed at underlying pathophysiological mechanisms and
treatment in general has to be considered as merely beingorgan supportive. In order to improve results and render
novel types of intervention, increased knowledge on
mechanisms including involved cells, chemokines, cyto-
kines and stromal components, during different phases of
ALI, may render novel and more targeted types of therapy,
probably to be used in a multimodal fashion.Conflict of interest statement
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